

1 **Title page:**

2 Full title: Impact of statin withdrawal on perceived and objective muscle function

3 Short title: Statin withdrawal and perceived and objective muscle function

4 Paul Peyrel^{1,2}, Pascale Mauriège^{1,2}, Jérôme Frenette^{3,4}, Nathalie Laflamme³, Karine
5 Greffard³, Sébastien S. Dufresne⁶, Claire Huth^{1,2}, Jean Bergeron^{3,5}, Denis R. Joanisse^{1,2,*}

6

7 ¹Department of Kinesiology, Université Laval, Québec, Québec, Canada

8 ²Research Center of the University Institute of Cardiology and Pulmonology of Quebec,
9 Québec, Québec, Canada

10 ³CHU de Québec – Université Laval Research Center, Québec, Québec, Canada

11 ⁴Department of Rehabilitation, Université Laval, Québec, Québec, Canada

12 ⁵Department of Laboratory Medicine and of Medicine, Université Laval, Québec, Québec,
13 Canada

14 ⁶Department of Health Sciences, Université du Québec à Chicoutimi, Saguenay, Québec,
15 Canada

16

17 * Corresponding author:

18 Email: denis.joanisse@kin.ulaval.ca (DRJ)

19 **Abstract**

20 Background and Aims: Statin-associated muscle symptoms (SAMS) are frequently
21 reported. Nevertheless, few data on objective measures of muscle function are available.
22 Recent data suggesting an important nocebo effect with statin use could confound such
23 effects. The objective was to assess if subjective and objective measures of muscle function
24 improve after drug withdrawal in SAMS reporters.

25 Methods: Patients (59 men, 33 women, 50.3±9.6 yrs.) in primary cardiovascular prevention
26 composed three cohorts: statin users with (SAMS, n=61) or without symptoms (No SAMS,
27 n=15), and controls (n=16). Force (FO), endurance (EN) and power (PO) of the leg
28 extensors (EXT) and flexors (FLE) and handgrip strength (FOHG) were measured using
29 isokinetic and handheld dynamometers, respectively. A 10-point visual analogue scale
30 (VAS) was used to self-assess SAMS intensity. Measures were taken before and after two
31 months of withdrawal.

32 Results: Following withdrawal, repeated-measures analyses show improvements for the
33 entire cohort in ENEXT, ENFLE, FOFLE, POEXT and POFLE (range +7.2 to +13.3%, all
34 $p \leq 0.02$). Post-hoc analyses show these changes to occur notably in SAMS (+8.8 to
35 +16.6%), concurrent with a decrease in subjective perception of effects in SAMS (VAS,
36 from 5.09 to 1.85). FOHG was also improved in SAMS (+4.0 to +6.2%) when compared
37 to No SAMS (-1.7 to -4.2%) (all $p=0.02$).

38 Conclusions: Whether suffering from “true” SAMS or nocebo, those who reported SAMS
39 had modest but relevant improvements in muscle function concurrent with a decrease in
40 subjective symptoms intensity after drug withdrawal. Greater attention by clinicians to
41 muscle function in frail statin users appears warranted.

42 **1. Introduction**

43 Among the pharmacological approaches used to treat hypercholesterolemia, statins are
44 considered the reference lipid-lowering drugs (1). By significantly reducing cholesterol
45 synthesis through HMG-CoA reductase inhibition, they are commonly used as part of
46 primary or secondary prevention to limit the risk of cardiovascular disease (CVD). Statins
47 are now used by over 200 million people around the world (2), but controversies remain
48 on the nature and prevalence of their side effects. These effects can include the
49 development of diabetes, elevated circulating liver enzymes and joint pain (3, 4), but statin-
50 associated muscle symptoms (SAMS) are the most frequently reported side effects of statin
51 use. Mild myalgia has often been reported by 5-10% of statin users (4, 5), this rate reaching
52 around 20% in a few reports (6, 7).

53 That statin use could lead to a variety of mild or moderate muscle symptoms is not
54 surprising. Indeed, myopathies and rhabdomyolysis have been documented from statin use
55 (8-10), giving credence to the idea that less severe symptoms are possible or even likely.
56 Nevertheless, recent work has called into question the true prevalence of SAMS, as
57 distinguishing between the harmful effects truly associated with statins and the so-called
58 nocebo effect is not trivial (11-14). It is thus essential to develop strategies in order to
59 identify the “true” statin-intolerant patients (15). Among those proposed is the recent
60 “SAMS - Clinical Index” (SAMS-CI) (16) which purports to classify the origin of muscle
61 pain according to whether it is “unlikely”, “possibly” or “probably” related to statin use.
62 This tool remains to be validated for use in a broad patient population.

63 While statins promote an increase in reported muscle complaints, in different muscle
64 groups (especially pectorals, quadriceps, biceps, and deltoids) (17), they do not appear to

65 lead to a systematic decrease in strength or endurance, physical activity level or
66 performance (18-23). A recent study by Kawai et al. (2018) (24) assessed the physical
67 performances of 1,022 adults aged between 65 and 88 yrs., depending on whether the
68 participants were using statins or not. In this study, significantly lower handgrip strength
69 (respectively 26.1 ± 7.4 kg and 28.1 ± 8.5 kg, mean \pm standard deviation [SD]) and normal
70 walking speed (respectively 1.30 ± 0.24 m/s and 1.36 ± 0.26 m/s) were observed between
71 statin users compared with non-users. However, when these data were adjusted for SAMS
72 risk factors (age, sex, body mass index [BMI], and number of medications), differences
73 were lost, suggesting that SAMS were contributory to these effects.

74 The current state of the scientific literature is both limited and contradictory. Some
75 studies suggest that SAMS have no impact on muscle performance (25, 26). However, as
76 illustrated by Parker et al. (2013), a reduction in performance has been previously
77 demonstrated in patients reporting SAMS in some observational studies (22). Nevertheless,
78 in the work of Parker et al. (2013), while a decrease in 5 of the 14 performance variables
79 studied did occur in statin patients reporting SAMS (n=18), 4 performance variables also
80 deteriorated in patients reporting muscle symptoms in the placebo group (n=10). In general,
81 the probability that studies examining the muscle function effects of statins include both
82 true SAMS-sufferers and nocebo reporters certainly is a limiting factor in the current
83 understanding of this phenomenon.

84 The present study therefore aimed first to focus on the effects of statin withdrawal on
85 perceived SAMS and objective muscle performance, and second to explore the impact of
86 this manipulation according to the SAMS-CI category.

87 **2. Methods**

88 **2.1 Participants**

89 Caucasian men (n=59) and women (n=33) aged 30 to 60 years (50.3±9.6 yrs. [mean ±
90 SD]) and affiliated to the cardiovascular (CV) lipid prevention clinic at the CHU de
91 Québec-Université Laval (CHUL) were enrolled. These were patients treated with statins
92 in primary CV prevention and with normal blood creatine kinase (CK) levels. Two statin
93 groups were formed: a first self-reporting SAMS (SAMS, n=61) and a second without
94 SAMS (No SAMS, n=15). A third group of participants not taking statins served as controls
95 (Controls, n=16). In this work, data are pooled from a pilot study and a main study (Fig 1).
96 In both studies, the inclusion and exclusion criteria and procedures, with a few exceptions
97 mentioned below, were the same. Participants had to be in good general health, sedentary
98 or moderately active (i.e., less than one hour of leisure-time physical activity performed
99 per week) and to present no contraindications for physical function testing. Patients were
100 required to have a low or moderate Framingham risk score, which allowed the research
101 team to modify their lipid-lowering regimen for the study period. Finally, patients who
102 were previously prescribed other statins or doses prior to their current regimen were not
103 excluded. However, self-reported SAMS needed to be temporally associated with statin
104 use and be present with the current prescription.

105 Participants were excluded from the study if they had taken other lipid-lowering drugs
106 or any natural treatment that affects lipid metabolism in the last year. Other exclusion
107 criteria included vitamin D deficiency (calcifediol (25(OH)D₃) levels below 12.5nmol/L)
108 or vitamin D supplementation; elevated circulating CK levels (>170u/L for women;
109 >195u/L for men) or a history of elevated CK of known or unknown etiology; hepatic or

110 renal failure; untreated hypo- or hyperthyroid; any treatment promoting an increased risk
111 of myopathy; any infection requiring the use of an antibiotic; a daily consumption of more
112 than 60mL of grapefruit juice; hereditary muscle disorders or myopathy, polymyositis or
113 inflammatory myopathy; use of corticosteroids; comorbidities leading to muscle or bone
114 pain (fibromyalgia, arthritis, sensory or intrinsic neuropathy, spinal disease, loss of
115 reflexes, atrophy muscle group); unexplained cramps; cancer in the five years prior to
116 entry into the study; diabetes, stroke, or any known sickle cell trait. In addition, pregnancy,
117 breastfeeding, a physical disability or previous injury interfering with stress testing,
118 depression (within the past three years) or treatment with antidepressants, the use of
119 antipsychotic drugs and alcohol abuse were also exclusion factors.

120 In a subset of participants (n=22) for which data were available, comparisons based on
121 SAMS-CI category were performed for SAMS-reporting participants (16).

122 The protocol was approved by the CHU de Québec – Université Laval ethics committee,
123 and all participants provided informed written consent. The study design complied with the
124 principles of the Declaration of Helsinki and was registered in clinicaltrials.gov
125 (NCT01493648). Recruitment and data acquisition were conducted from October 2011 to
126 October 2015.

127

128 <insert Fig 1 here>

129 **Fig 1.** Diagram of patients' recruitment

130 M: men; SAMS: statin-associated muscle symptoms; W: women.

131

132 **2.2 Procedures**

133 Participants first participated in an inclusion visit. Height (stadiometer), body mass
134 (calibrated scale), BMI (kg/m²), and waist circumference (WC) were assessed (weight,
135 BMI, and WC were not measured after statin withdrawal in the pilot study). Participants
136 completed a standardized recruitment questionnaire, based on current statin type and
137 dosage, statins use history, predisposing conditions or factors that could contribute to
138 muscle problems, as well as an assessment of eating habits.

139 The experimental protocol consisted of two months of statin withdrawal with pre- and
140 post-withdrawal assessments of subjective and objective measures of muscle function and
141 blood levels of several markers of interest. Data were collected by a blinded experimenter.
142 On the day of pre-test, participants were instructed to take their usual dose of statin at their
143 habitual time. The two-month interval was based on previous studies that showed most
144 SAMS appeared or were resolved within this period of the introduction or withdrawal of
145 the medication (5, 27).

146

147 ***2.3 Measurements***

148 *2.3.1 Self-reported muscle symptoms*

149 Participants self-reported the presence of SAMS by describing what symptom(s) they
150 believed to be the result of medication use. These symptoms typically included myalgia,
151 stiffness, weakness, fatigue and/or cramps. They were then asked to rate the intensity of
152 the symptom(s) they reported by answering the following question (translated from French)
153 on a visual analog scale (VAS):

154 *On a scale of 0 to 10 (10 being the most intense or unbearable), rate the current intensity*
155 *of the symptom(s) which you believe to be related to statin use*

156

157 *2.3.2 Blood tests*

158 A venipuncture was performed following a 12-h overnight fast and prior to muscle
159 function tests. The levels of a number of circulating factors were assessed from these
160 samples (Table 1 and S1 Table), including markers of muscle (CK and myoglobin [MB])
161 and liver (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) damage,
162 the plasma lipid-lipoprotein profile (total cholesterol [TC]; triglycerides [TG]; high density
163 lipoprotein [HDL]; low-density lipoprotein [LDL]; TC/HDL; apolipoprotein B-100
164 [APOB-100] and apolipoprotein A1 [APOA1]), and 25(OH)D₃. Only ALT, AST and CK
165 were assessed in the pilot study. All were measured using standardized clinical assays at
166 the CHU de Québec – Université Laval clinical laboratory.

167

168 *2.3.3 Muscle performance*

169 Muscle performance was assessed using a Biodex isokinetic dynamometer (Biodex
170 Medical Systems, Shirley, NY). The system has shown good reproducibility in the healthy
171 population (28). Patients were seated in an upright position and the resistance pads were
172 aligned according to the manufacturer's instructions. The maximum force (FO), power
173 (PO) and endurance (END) of the extensor (EXT) and flexor (FLE) muscles of the
174 dominant leg were measured.

175 Testing began with a warm-up consisting of five repetitions at 60°/s including one
176 movement at maximum voluntary contraction (MVC). Subsequently, the maximum force
177 (Nm) was measured during three MVCs each at 60°/s and 180°/s. The highest measured
178 value was retained. Endurance and power were measured over 15 MVC repetitions at

179 180°/s. Endurance was calculated as the total (sum) of strength developed during all 15
180 repetitions (Nm). Power was calculated (W) by multiplying the endurance value with the
181 total time required for the patient to complete the repetitions; then divided by the number
182 of repetitions (n=15). For all tests, each maximum contraction was performed within the
183 first 90 degrees of the knee's range of motion.

184

185 *2.3.4 Handgrip strength*

186 Handgrip strength was measured with a Jamar hydraulic hand dynamometer (Asimov
187 Engineering, Los Angeles, CA). This tool is reliable and validated (29). Patients performed
188 the test seated with their feet slightly apart, the unassessed arm at their side, the arm
189 assessed at 90° and not resting on an armrest. The handle of the dynamometer was adjusted
190 so that the handle rested on the middle of the four fingers while positioning the base of the
191 dynamometer on the first metacarpal. Once in position, the patient was asked to squeeze
192 the handle of the dynamometer as hard as possible for 3s while exhaling. One min of rest
193 between each contraction was respected. The best of the three repetitions was retained to
194 assess handgrip force (kg) in the right (FOHGR) and left (FOHGL) hands In the pilot study,
195 handgrip strength was only measured in the dominant hand.

196

197 *2.4 Statistical analyses*

198 Data are expressed as mean \pm SD. Sample size calculations were performed using
199 predicted changes to measures of physical performance following statin withdrawal. Using
200 a one-tailed model with p=0.01 and a power of 80% and aiming for a 20% average increase

201 in several muscle function tests using observed standard deviations (SD) from preliminary
202 data from 9 participants, required total n values were found to range from 15 to 30.

203 All statistical analyses were performed using JMP software (SAS Institute, Cary, NC).
204 In cases of missing data for any given measure, participants were removed from that
205 analysis. Between group differences for variables not measured repeatedly over time were
206 analyzed by ANOVA followed by Tukey post-hoc tests. A repeated measures factorial
207 design was used to assess differences between groups and over time using the “Full
208 factorial mixed design” add-in for JMP (30), and post-hoc analyses performed using Tukey
209 tests. Chi-square tests were used to assess distribution differences across groups from
210 contingency tables. These latter tests were not performed when expected observations in a
211 cell fell below $n=5$. All results were considered statistically significant when p reached
212 <0.05 . Finally, Cohen's d values for pairwise comparisons were used to assess effect sizes
213 (ES) for within-group changes over time and to qualify changes as trivial (Cohen's $d <0.2$),
214 small (0.2-0.5), moderate (0.5-0.8), or large (>0.8).

215 **3. Results**

216 **3.1. *Anthropometric and metabolic variables at baseline***

217 Participants' characteristics are shown in Table 1. Whereas the SAMS group was
218 significantly older on average (+10.6 yrs.) than the Control group, the No SAMS group
219 was intermediate (5.4 yrs. younger than SAMS) but not significantly different from the
220 other two groups. Overall, the SAMS group presented a slightly more deteriorated health
221 profile, as revealed by higher BMI (+4.1kg/m²) compared to the No SAMS group.
222 Increased adiposity in the SAMS group was also indicated by a greater WC, on average
223 +11.2 cm more than that of the No SAMS and Control groups (p=0.01). Despite a
224 significantly higher ALT level in the SAMS group compared to other groups, all markers
225 of muscle and liver injuries (CK, MB, AST, and ALT) were below values of clinical
226 concern. Finally, 25(OH)D₃ values did not differ between groups and were not indicative
227 of vitamin D deficiency.

228

Table 1. Pre- and post-statin withdrawal anthropometric characteristics and metabolic variables

	SAMS			No SAMS			Controls			ANOVA		
	Pre	Post	ES	Pre	Post	ES	Pre	Post	ES	Time	Category	T*C
Men/Women, n	38/23			10/5			11/5			p	p	p
Age (years)	53.0 ± 8.4 ^a	-	-	47.6 ± 9.6 ^{ab}	-	-	42.4 ± 9.4 ^b	-	-	-	0.87 ^s	-
Anthropometric characteristics												
n	37 to 59			14 to 15			14 to 15					
Height (cm)	166 ± 13 ^a	-	-	172 ± 8 ^a	-	-	169 ± 8 ^a	-	-	-	0.20	-
Weight (kg)	80.9 ± 14.7	80.8 ± 14.7	0.00	74.0 ± 12.3	73.9 ± 12.0	-0.01	74.8 ± 13.3	74.8 ± 13.9	-0.01	0.76	0.10	0.97
BMI (kg/m ²)	29.2 ± 4.5	29.0 ± 4.5	-0.06	25.1 ± 3.2	25.1 ± 3.2	0.00	26.9 ± 5.9	26.9 ± 5.9	0.00	0.56	0.01	0.66
WC (cm)	95.4 ± 17.2	93.9 ± 10.1	-0.07	86.2 ± 11.1	86.4 ± 11.5	0.01	84.3 ± 13.0	85.1 ± 13.8	0.05	0.93	<0.01	0.77
Plasma metabolic variables												
n	41 to 60			14			15					
MB (µg/L)	29.9 ± 11.0	28.5 ± 9.3	-0.13	29.5 ± 10.7	27.9 ± 11.9	-0.18	33.7 ± 18.1	30.8 ± 10.4	-0.08	0.13	0.46	0.84
CK (U/L)	130 ± 76	126 ± 90	-0.11	132 ± 62	118 ± 46	-0.17	163 ± 112	162 ± 88	0.06	0.19	0.25	0.65
ALT (U/L)	30.0 ± 17.6	26.9 ± 15.6 [*]	-0.22	23.6 ± 12.0	19.1 ± 8.2	-0.30	18.6 ± 5.5	18.4 ± 6.3	-0.04	<0.01	0.02	0.20
AST (U/L)	22.5 ± 5.9	21.7 ± 6.4	-0.17	22.0 ± 6.3	20.6 ± 5.3	-0.20	19.7 ± 5.1	18.5 ± 4.2	-0.15	0.04	0.15	0.92
TC (mmol/L)	4.81 ± 0.98	6.78 ± 1.34 [*]	1.73	4.60 ± 0.84	6.85 ± 1.37 [*]	1.92	5.06 ± 0.83	5.21 ± 0.93	0.16	<0.01	0.04	<0.01
TG (mmol/L)	1.89 ± 1.22	2.19 ± 1.20	0.31	1.08 ± 0.54	1.66 ± 0.90	0.70	1.15 ± 1.05	1.20 ± 1.07	0.03	<0.01	<0.01	0.22
HDL (mmol/L)	1.31 ± 0.37	1.31 ± 0.35	-0.01	1.55 ± 0.42	1.49 ± 0.44	-0.16	1.56 ± 0.41	1.63 ± 0.42	0.16	0.93	0.03	0.08
LDL (mmol/L)	2.71 ± 0.97	4.59 ± 1.31 [*]	1.86	2.56 ± 0.71	4.61 ± 1.26 [*]	2.02	3.11 ± 0.92	3.18 ± 1.03	0.04	<0.01	0.26	<0.01
TC/HDL (mmol/L)	3.95 ± 1.36	5.54 ± 1.80 [*]	1.10	3.09 ± 0.64	4.82 ± 1.07 [*]	1.85	3.48 ± 1.26	3.45 ± 1.33	-0.04	<0.01	<0.01	<0.01
APOB-100 (g/L)	0.93 ± 0.26	1.41 ± 0.33 [*]	1.69	0.87 ± 0.17	1.36 ± 0.28 [*]	2.13	0.91 ± 0.22	0.93 ± 0.28	0.05	<0.01	<0.01	<0.01
APOA1 (g/L)	1.47 ± 0.22	1.44 ± 0.24	-0.11	1.56 ± 0.24	1.54 ± 0.25	-0.09	1.61 ± 0.23	1.60 ± 0.20	0.00	0.36	0.09	0.81
25(OH)D ₃ (mmol/L)	74.2 ± 32.5	68.4 ± 32.0 [†]	-0.18	71.2 ± 27.0	63.8 ± 25.0	-0.25	66.9 ± 18.7	68.3 ± 19.2	0.06	0.02	0.91	0.12
Self-reported muscle symptoms intensity												
n	60			14			15					
VAS (0 to 10)	5.09 ± 1.81	1.85 ± 2.25 [*]	-1.22	0.00 ± 0.00	0.00 ± 0.00	/	0.00 ± 0.00	0.00 ± 0.00	/	<0.01	<0.01	<0.01

230 Data are expressed as mean ± standard deviation; \$ P-value is shown here by a chi-squared test; Post value with * is statistically different

231 from the pre value with p≤0.01; Post value with † is statistically different from the pre value with p<0.05. ALT: alanine aminotransferase;

232 APOA1: apolipoprotein A1; APOB-100: apolipoprotein B-100; AST: aspartate aminotransferase; BMI: body mass index; WC: waist
233 circumference; CK: creatin kinase; ES: effects size; HDL: high-density lipoprotein; LDL: low-density lipoprotein; MB: myoglobin;
234 SAMS: statin-associated muscle symptoms; TC: total cholesterol; TC/HDL: cholesterol total / HDL cholesterol; TG: triglycerides; VAS:
235 visual analogic scale; 25(OH)D₃: Calcifediol.

236

237 **3.2. *Clinical aspects of statin users***

238 Most statin users in this study were prescribed rosuvastatin (50% of participants) or
239 atorvastatin (35.5%). This distribution was expected given the usual clinical practice at the
240 CHU de Québec – Université Laval lipid clinic. A detailed breakdown of the clinical profile
241 of participants in this study is presented in S2 Table.

242 The Framingham Score revealed that the CV risk over ten years was low (<10%) for
243 all patients (except for 1 patient [13%, moderate risk]). Nevertheless, the CV risk for the
244 SAMS group was on average 1.43% and 1.96% higher than that of the No SAMS and
245 Control groups, respectively. Most participants in the SAMS and No SAMS groups had
246 been using statins for 12 to 48 months (80.4% and 100% respectively). Nineteen
247 participants indicated having previously not tolerated some forms of statins, their
248 distribution being roughly equal in SAMS and No SAMS groups (respectively 31.9% and
249 26.7% of participants). Among the 38 participants with a family history (first degree) of
250 CVD, 35 were present in groups treated with statins. 91.3% of participants with a family
251 history (first degree) in terms of lipid-lowering treatment were present in these same statin-
252 taking groups. Finally, of the 30 participants in the SAMS group who reported a family
253 history (first degree) of lipid-lowering therapy, 6 also reported a self-reported family
254 history of SAMS.

255

256 **3.3. *Statin withdrawal effects on anthropometry and metabolic variables***

257 No changes to anthropometric measures were observed following statin withdrawal in
258 either the SAMS or No SAMS groups (Table 1).

259 In addition, and as expected, a significant deterioration of the lipid-lipoprotein profile
260 was seen in all statin users following drug withdrawal. Indeed, repeated-measures ANOVA
261 analyses revealed several time, category, and time x category interactions for most lipids
262 (Table 1). In brief, while no change was observed in any lipid levels studied in the control
263 group in the same period, both SAMS and No SAMS statin users experienced a deteriorated
264 lipid-lipoprotein profile, reflected by increased TC, TG, LDL, TC/HDL, and APOB-100
265 levels following medication withdrawal. HDL and APOA1 levels remained, however,
266 unchanged.

267 With respect to markers of tissue damage or dysfunction, while ALT and AST levels
268 are somewhat reduced following withdrawal of the drug, these values always remained
269 well below clinical thresholds. The muscle damage specific markers MB and CK did not
270 differ across groups or change following statin withdrawal and remained well below
271 clinical values of clinical concern throughout the study (Table 1).

272 Finally, despite a small decrease in 25(OH)D₃ levels in the statin groups, these values
273 remained not different from those of the control group and were not indicative of vitamin
274 D deficiency. The baseline levels and impact of statin withdrawal on several other plasma
275 variables are presented in S1 Table.

276

277 **3.4. *Perceived muscle effects and objective physical performance***

278 As depicted in Table 1, a significant improvement in the perception of muscle
279 symptoms following statin withdrawal was observed in the SAMS group, decreasing by
280 3.24 units on the 10-point scale.

281 Results related to objective physical performance showed significant time effects for
282 all Biodex isokinetic dynamometer measures: ENEXT (+8.17% overall for the entire group
283 [ES: 0.22, small effect]), ENFLE (+11.6% [ES: 0.30, small effect]), FOFLE (+7.20% [ES:
284 0.22, small effect]), POEXT (+9.04% [ES: 0.24, small effect]) and POFLE (+13.3% [ES:
285 0.34, small effect]), except for FOEXT (+3.24%, NS, [ES: 0.11, trivial effect]) (Fig 2).
286 However, few between group differences were seen at baseline, with only ENFLE and
287 POFLE being slightly lower in the SAMS group. Although there was no time x category
288 interaction for any of these measures, post-hoc analyses revealed statistically significant
289 within-group improvements only in the SAMS group following statin withdrawal, and this
290 was true for five of the six isokinetic dynamometer measures (improvement range +8.8 to
291 16.6%, [ES: 0.25 to 0.39, all small effects]).

292 In terms of handgrip performance, although neither left (FOHGL) nor right (FOHGR)
293 force showed any time or category effects, a significant interaction was observed for
294 FOHGL, and this reached near statistical significance ($p=0.06$) for FOHGR. In both cases,
295 the greatest increase in force following statin withdrawal was seen in the SAMS group
296 (+4.0% for FOHGR [ES: 0.09, trivial effect]; +6.2% for FOHGL, [ES: 0.18, trivial effect]),
297 while values decreased in the No SAMS group (-4.2% for FOHGR [ES: -0.16, trivial
298 effect]; -1.7% for FOHGL [ES: -0.06, trivial effect]). Indeed, if repeated-measure analyses
299 are done without the Control group, the time x category interactions become statistically
300 significant both for the right and left hands (all $p=0.02$).

301

302

<insert Fig 2 here>

303 **Fig 2.** Pre- and post-statin withdrawal measures of physical performance

304 Data are expressed as mean \pm standard error; Post value with * is statistically different from
305 pre value with $p \leq 0.01$; Post value with † is statistically different from pre value with
306 $p < 0.05$; ENEXT: endurance in extension (panel A); ENFLE: endurance in flexion (panel
307 B); FOEXT: force in extension (panel C); FOFLE: force in flexion (panel D); FOHGL:
308 hand grip force left (panel H); FOHGR: hand grip force right (panel G); POEXT: power in
309 extension (panel E); POFLE: power in flexion (panel F); SAMS: statin-associated muscle
310 symptoms.

311

312 In order to establish whether observed changes in muscle functions are of clinical
313 relevance, we codified as clinically significant any improvement greater or equal to 15%
314 from baseline for any measure in a given individual (31). The number of patients from the
315 two statin-using groups showing such improvements is reported in Table 2, and
316 contingency analyses revealed that for five of the eight physical performance measures, the
317 number of patients who experienced a clinical improvement in performance following
318 statin weaning was statistically higher in the SAMS group.

319

320 **Table 2.** Proportion of patients who display clinically relevant performance

321 improvements following statin withdrawal

	SAMS n / total (%)	No SAMS n / total (%)	Category p
ENEXT	23/54 (42.6)	2/13 (15.4)	0.05
ENFLE	28/54 (51.9)	4/13 (30.8)	0.17
FOEXT	9/54 (16.7)	1/13 (7.69)	0.38
FOFLE	13/54 (24.1)	2/13 (15.4)	0.49
POEXT	22/54 (40.7)	1/13 (7.69)	0.01
POFLE	29/54 (53.7)	3/13 (23.1)	0.04
FOHGR	6/32 (18.8)	0/12 (0.00)	0.04
FOHGL	7/25 (28.0)	0/12 (0.00)	0.01

322 Data are expressed as the number of patients with a 15% improvement in performance
323 following statin withdrawal / total number of patients in the considered group; p-values are
324 shown here by a chi-squared test. SAMS: statin-associated muscle symptoms; For the other
325 abbreviations, see legends to Fig 2.

326

327 **3.5. Targeting “real” sufferers of SAMS**

328 For a subset (n=22) of SAMS-reporting patients, available data allowed us to assess the
329 likelihood of their symptoms being truly caused by statins using the SAMS-CI (16). Given
330 very low numbers in the “unlikely” category, they were pooled with the “possible”
331 category for analyses. Subjective perception of symptoms resolution was greater in the
332 patients classified as “probable” for suffering from true SAMS using this classification
333 scheme (Fig 3). However, despite improvement in five of eight measures of physical
334 performance following statin withdrawal, we did not observe any significant difference
335 between categories or category x time interactions in repeated measures analyses (Fig 4).

336

337 <insert Fig 3 here>

338 **Fig 3.** Impact of statin withdrawal on perceived SAMS intensity by SAMS-CI category
339 using a visual analog scale from 0 to 10

340 Data are expressed as mean \pm standard error; Post value with * is statistically different from
341 pre value; SAMS: statin-associated muscle symptoms; SAMS-CI: SAMS – clinical index.

342

343 <insert Fig 4 here>

344 **Fig 4.** Impact of statin withdrawal on physical performance by SAMS-CI category

345 Data are expressed as mean \pm standard error; Post value with * is statistically different from
346 pre value with $p \leq 0.01$; Post value with † is statistically different from pre value with
347 $p < 0.05$; SAMS-CI: statin-associated muscle symptoms – clinical index; For the other
348 abbreviations, see legends to Fig 2.

349 **4. Discussion**

350 In the face of frequent reports of SAMS (4-7), few objective data have shown negative
351 impacts of statins on muscle performance. Here we present evidence for modest but
352 relevant improvements on muscle function following statin withdrawal in patients self-
353 reporting SAMS. Indeed, despite the lack of change in biochemical markers or clinical
354 indication of tissue damage, we observe for the entire cohort an overall improvement over
355 time following withdrawal in muscle functions for several objective measures of knee
356 extension and flexion (Fig 2). However, upon closer inspection, the greatest improvements
357 were observed in the SAMS group; in fact, within-group analyses showed no statistically
358 significant changes in the No SAMS and Control groups over time. Although the impact
359 of SAMS on performance remains debatable in the literature, our data aligned with those
360 of Parker et al. (2013) that showed differences in leg strength during isokinetic movements
361 in extension at 60°/s and 180°/s and flexion at 60°/s between atorvastatin-treated
362 participants with or without muscle complaints (22). It is perhaps not surprising that we
363 observed an impairment in knee extension and flexion performances, as it has been shown
364 that SAMS tend to affect large muscle groups such as the quadriceps (17). Nevertheless,
365 and unlike that was reported by Parker et al. (2013) (22), we also observed significant
366 though modest improvements in handgrip strength in the SAMS reporting group.

367 Using a cut-off value (15%) which can be considered clinically relevant and a value
368 greater than what is expected from test habituation, we showed a clearly greater proportion
369 of patients showing improvement in objective measures of muscle performance when
370 reporting SAMS (Table 2). Though the average values of the improvements are modest,
371 they are potentially important because they result in a decrease in the potential to perform

372 daily activities. Also, as muscle performance decreases with aging, the impact of such a
373 decrease in performance with statin use could be clinically more significant in this
374 population, which certainly merits further examination.

375 Our data must, of course, be nuanced in the context of a growing body of evidence for
376 a large nocebo effect in patients self-reporting SAMS (12-14, 32). For example, the work
377 of Howard et al. (2021) showed that most symptoms induced by statins were nocebo (32).
378 In the study, the investigators set up a 12-month multi-crossover trial in which 46 patients
379 in primary CV prevention and 14 patients in secondary CV prevention (65.5±8.6 yrs.) were
380 randomized in three conditions: statin, placebo, and no treatment. Every day, patients were
381 asked to rate the intensity of statin-associated symptoms (SAS). Results notably showed
382 differences in self-reported SAS intensity between the statin vs. no treatment and placebo
383 vs. no treatment conditions ($p < 0.01$), though no difference between the placebo and statin
384 conditions was observed ($p = 0.39$). Though their work studied patients who reported SAS,
385 it did not specifically focus on SAMS. Whether or not our patients suffered of “true” SAMS
386 or a confounding nocebo effect, our data showing an objective impact of statin withdrawal
387 on self-reported symptoms intensity and objective measures is of important potential
388 clinical relevance. Indeed, recognizing that a patient could be suffering, objective impacts
389 on muscle functions could and should be considered in treatment assessment and follow
390 up.

391 It is of great importance to develop or validate tools that purport to identify likely
392 sufferers of “true” SAMS (15). In this regard, a subset of our data allowed us to classify
393 participants according to the SAMS-CI, a tool that has been proposed as potentially useful
394 in a clinical setting but has yet to be validated (16). Using this approach, while we did

395 observe a greater improvement in subjective symptoms resolution in those classified as
396 "probably" suffering from SAMS (Fig 3), we did not see any difference in objective
397 measures between categories (Fig 4). These results should be interpreted with great caution
398 as our analyses are weakened by a relatively low number of participants. Nevertheless, the
399 demonstration of a greater subjective impact in the “probably” group does warrant further
400 study on the potential usefulness of the SAMS-CI.

401 This study has several strengths. First, the lipid data indicate that we can be confident
402 about compliance with statin withdrawal. Second, the inclusion of a No SAMS group and
403 a Control group allows a more rigorous analysis and interpretation of results, even if these
404 groups are somewhat smaller. Third, the use of validated and standardized sensitive
405 objective measures allows us to discern little but real effects in muscle function. This study
406 is also, to our knowledge, the first work to attempt to validate the SAMS-CI. Finally, the
407 population recruited here represents a typical population of primary CV prevention patients
408 treated with statins, which reinforces the clinical relevance of our data.

409 A limitation of this study is that recruitment was based on self-reporting of SAMS.
410 Even if we limited the sources of bias using various recruitment criteria, we cannot be
411 certain of the potential influence of the nocebo effect on our results. On the other hand,
412 considering the growing interest in patient-reported outcomes in clinical studies and
413 especially their unique ability to be a true reflection of a “patient-centered approach” (33),
414 further insights into how individuals experience their SAMS and respond to quantitative
415 changes in objective clinical measures can enrich and clarify the evidence from quantitative
416 measures. This knowledge could be used in the future to develop intervention strategies
417 and lifestyle advice tailored to the individual needs of people receiving statin therapy.

418 Another potential cofounder is that the SAMS group was older and presented greater
419 markers of adiposity, which could have influenced some of the results. While the sample
420 studied in this report is typical of the patients' population at our lipid clinic, and thus
421 includes a variety of statins and doses, we cannot exclude differential impacts of these
422 varying formulations on our measures. Also, although all patients were sedentary and were
423 instructed not to change their physical activity habits during the protocol, this was not
424 objectively monitored, which may be a source of intra- and inter-patient variability. In
425 addition, the relatively small number of participants, particularly in the control and No
426 SAMS groups, and especially in the SAMS-CI sub-analysis, limits our statistical power
427 and could have masked the significance of some of the results. The small number of
428 participants also did not allow for rigorous analyses by sex (although in the SAMS group,
429 baseline analyses did not indicate sex differences in response to drug withdrawal; data not
430 shown). Furthermore, all participants were Caucasian. While we also limited the
431 recruitment to patients between 30 and 60 yrs., primarily to avoid confounding effects of
432 conditions such as sarcopenia on muscle performance measures, this reduces the
433 generalizability of our findings. Our protocol is limited to a short follow-up of two months
434 with two visits (pre- and post-drug withdrawal). A longer follow-up could have led to
435 different conclusions. Finally, our protocol does not allow us to explore or discuss the
436 mechanisms of "true" SAMS.

437 **5. Conclusions**

438 Whether or not our study population suffered from “true” SAMS or placebo effects, our
439 data indicate that participants who self-reported SAMS had improved physical function
440 concurrent with decreased subjective symptom intensity following drug withdrawal.
441 Although the negative impacts of statins on muscle function appear small, these could
442 nonetheless have real and substantive effects in certain patients or patient populations. For
443 example, in patients who have experienced sarcopenia or dynapenia, such as the frail
444 elderly or others suffering from various muscle diseases, an additional loss of even a small
445 portion of their functional capacity could contribute to important loss of independence and
446 health-related quality of life (HRQoL). Given the relative ease with which handgrip
447 strength can be measured, the present data certainly warrant future studies on its potential
448 clinical value in assessing functional changes with statin use in these populations.

449 Clearly, the present results need to be validated or recreated in other studies. More
450 prospective data are needed, perhaps in the context of a randomized double-blinded study.
451 Furthermore, they need to be expanded to other statin populations, for example older
452 patients or those in secondary prevention. It also remains of great interest to further efforts
453 to better identify “true” SAMS sufferers and to assess whether functional impacts are
454 greater in this group. Finally, while we focus in this report on objective measures of muscle
455 functions, other impacts of self-reported SAMS such as those on HRQoL need further
456 study.

457 **Acknowledgements**

458 DRJ, JF and JB designed the study. NL provided clinical coordination, SSD, KG and
459 CH participated in data collection, CH managed data validation and entry, PP, CH and DRJ
460 performed statistical analyses. All participated in data interpretation. PP, under the
461 direction of DRJ and PM, wrote the manuscript. All authors critically reviewed and
462 accepted the final version of the article. The authors are grateful to patients for their
463 participation.

464 **References**

- 465 1. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al.
466 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA
467 Guideline on the Management of Blood Cholesterol: A Report of the American College of
468 Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
469 *Circulation*. 2019;139(25):e1082-e143.
- 470 2. Blaha MJ, Martin SS. How do statins work?: changing paradigms with implications
471 for statin allocation. *J Am Coll Cardiol*. 2013;62(25):2392-4.
- 472 3. Boulanger-Piette A, Bergeron J, Desgreniers J, Côté-Levesque M, Brassard D,
473 Joannisse DR, et al. [Statin intolerance and associated muscular dysfunctions]. *Med Sci*
474 (Paris). 2015;31(12):1109-14.
- 475 4. Thompson PD, Panza G, Zaleski A, Taylor B. Statin-Associated Side Effects. *J Am*
476 *Coll Cardiol*. 2016;67(20):2395-410.
- 477 5. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular
478 symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study.
479 *Cardiovasc Drugs Ther*. 2005;19(6):403-14.
- 480 6. Selva-O'Callaghan A, Alvarado-Cardenas M, Pinal-Fernandez I, Trallero-Araguas
481 E, Milisenda JC, Martinez MA, et al. Statin-induced myalgia and myositis: an update on
482 pathogenesis and clinical recommendations. *Expert Rev Clin Immunol*. 2018;14(3):215-
483 24.
- 484 7. Stoes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-
485 associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society

- 486 Consensus Panel Statement on Assessment, Aetiology and Management. *Eur Heart J.*
487 2015;36(17):1012-22.
- 488 8. Bouitbir J, Sanvee GM, Panajatovic MV, Singh F, Krahenbuhl S. Mechanisms of
489 statin-associated skeletal muscle-associated symptoms. *Pharmacol Res.* 2020;154:104201.
- 490 9. Taylor BA, Thompson PD. Statin-Associated Muscle Disease: Advances in
491 Diagnosis and Management. *Neurotherapeutics.* 2018;15(4):1006-17.
- 492 10. Turner RM, Pirmohamed M. Statin-Related Myotoxicity: A Comprehensive
493 Review of Pharmacokinetic, Pharmacogenomic and Muscle Components. *J Clin Med.*
494 2019;9(1).
- 495 11. Hauser W, Hansen E, Enck P. Nocebo phenomena in medicine: their relevance in
496 everyday clinical practice. *Dtsch Arztebl Int.* 2012;109(26):459-65.
- 497 12. Blacher J, Bruckert E, Farnier M, Ferrieres J, Henry P, Krempf M, et al. [Myalgia
498 and statins: Separating the true from the false]. *Presse Med.* 2019;48(10):1059-64.
- 499 13. Pedro-Botet J, Climent E, Benaiges D. Muscle and statins from toxicity to the
500 nocebo effect. *Expert Opinion on Drug Safety.* 2019;18(7):573-9.
- 501 14. Robinson JG. New insights into managing symptoms during statin therapy.
502 *Progress in Cardiovascular Diseases.* 2019;62(5):390-4.
- 503 15. Alonso R, Cuevas A, Cafferata A. Diagnosis and Management of Statin
504 Intolerance. *J Atheroscler Thromb.* 2019;26(3):207-15.
- 505 16. Rosenson RS, Miller K, Bayliss M, Sanchez RJ, Baccara-Dinet MT, Chibedi-De-
506 Roche D, et al. The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI):
507 Revision for Clinical Use, Content Validation, and Inter-rater Reliability. *Cardiovasc*
508 *Drugs Ther.* 2017;31(2):179-86.

- 509 17. Berent T, Berent R, Steiner S, Sinzinger H. Statin-induced muscular side effects at
510 rest and exercise - An anatomical mapping. *Atheroscler Suppl.* 2019;40:73-8.
- 511 18. Ashfield TA, Syddall HE, Martin HJ, Dennison EM, Cooper C, Aihie Sayer A. Grip
512 strength and cardiovascular drug use in older people: findings from the Hertfordshire
513 Cohort Study. *Age Ageing.* 2010;39(2):185-91.
- 514 19. Krishnan GM, Thompson PD. The effects of statins on skeletal muscle strength and
515 exercise performance. *Curr Opin Lipidol.* 2010;21(4):324-8.
- 516 20. Morville T, Dohlmann TL, Kuhlman AB, Sahl RE, Kriegbaum M, Larsen S, et al.
517 Aerobic Exercise Performance and Muscle Strength in Statin Users-The LIFESTAT Study.
518 *Med Sci Sports Exerc.* 2019;51(7):1429-37.
- 519 21. Noyes AM, Thompson PD. The effects of statins on exercise and physical activity.
520 *Journal of Clinical Lipidology.* 2017;11(5):1134-44.
- 521 22. Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, et al. Effect
522 of statins on skeletal muscle function. *Circulation.* 2013;127(1):96-103.
- 523 23. Williams PT, Thompson PD. Effects of Statin Therapy on Exercise Levels in
524 Participants in the National Runners' and Walkers' Health Study. *Mayo Clin Proc.*
525 2015;90(10):1338-47.
- 526 24. Kawai H, Ihara K, Kera T, Hirano H, Fujiwara Y, Tanaka M, et al. Association
527 between statin use and physical function among community-dwelling older Japanese
528 adults. *Geriatr Gerontol Int.* 2018;18(4):623-30.
- 529 25. Mallinson JE, Marimuthu K, Murton A, Selby A, Smith K, Constantin-Teodosiu D,
530 et al. Statin myalgia is not associated with reduced muscle strength, mass or protein
531 turnover in older male volunteers, but is allied with a slowing of time to peak power output,

- 532 insulin resistance and differential muscle mRNA expression. *J Physiol*. 2015;593(5):1239-
533 57.
- 534 26. Panza GA, Taylor BA, Dada MR, Thompson PD. Changes in muscle strength in
535 individuals with statin-induced myopathy: A summary of 3 investigations. *J Clin Lipidol*.
536 2015;9(3):351-6.
- 537 27. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, et al. Statin-
538 Associated Myopathy with Normal Creatine Kinase Levels. *Annals of Internal Medicine*.
539 2002;137(7):581–5.
- 540 28. Feiring DC, Ellenbecker TS, Derscheid GL. Test-Retest Reliability of the Biodex
541 Isokinetic Dynamometer. *Journal of Orthopaedic & Sports Physical Therapy*.
542 1990;11(7):298-300.
- 543 29. Mathiowetz V, Weber K, Volland G, Kashman N. Reliability and validity of grip
544 and pinch strength evaluations. *The Journal of Hand Surgery*. 1984;9(2):222-6.
- 545 30. Add-Ins J. Full Factorial Repeated Measures ANOVA Add-In 2014 [Available
546 from: [https://community.jmp.com/t5/JMP-Add-Ins/Full-Factorial-Repeated-Measures-
547 ANOVA-Add-In/ta-p/23904?trMode=source](https://community.jmp.com/t5/JMP-Add-Ins/Full-Factorial-Repeated-Measures-ANOVA-Add-In/ta-p/23904?trMode=source).
- 548 31. Li RC, Wu Y, Maffulli N, Chan KM, Chan JL. Eccentric and concentric isokinetic
549 knee flexion and extension: a reliability study using the Cybex 6000 dynamometer. *Br J*
550 *Sports Med*. 1996;30(2):156-60.
- 551 32. Howard JP, Wood FA, Finegold JA, Nowbar AN, Thompson DM, Arnold AD, et
552 al. Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment. *J Am*
553 *Coll Cardiol*. 2021;78(12):1210-22.

554 33. Cruz AC, Pedreira M. Patient-and Family-Centered Care and Patient Safety:

555 reflections upon emerging proximity. Rev Bras Enferm. 2020;73(6):e20190672.

556

557

558 **Supporting information**

559 The study was supported by the Canadian Institutes of Health Research (CIHR grant MOP
560 114917 to DRJ, JB, and JF [<https://cihr-irsc.gc.ca>]). The funders had no role in study
561 design, data collection and analysis, decision to publish, or preparation of the manuscript.
562 The authors have declared that no competing interests exist.
563

564 **List supporting information captions**

565 **S1 Table.** Pre- and post-statin withdrawal plasma variables

566 SAMS: statin-associated muscle symptoms; FFA: free fatty acids; FBGL: fasting blood
567 glucose level; INS: insulin; TSH: thyroid-stimulating hormone; PTH: parathormone;
568 eGFR: estimated glomerular filtration rate; CRP: C-reactive protein; RF: rheumatoid
569 factor; Cr: creatinine; UR: urea; PA: pyruvic acid; LAC: lactic acid; LDH: lactate
570 dehydrogenase; ALKP: alkaline phosphatase; Ca: calcium; Na: sodium; K: potassium; Mg:
571 magnesium; NH₄: ammonia; P: phosphorus; Cl: chloride; Data are expressed as mean ±
572 SD ; Post value with * is statistically different from the pre value with p≤0.01; Post value
573 with † is statistically different from the pre value with p<0.05.

574

575 **S2 Table.** Clinical profile of statin users

576 SAMS: statin-associated muscle symptoms; * Framingham Score: values are means ± SD and
577 ANOVA p=0.06.




Figure 1





Figure 2



ANOVA Time P	ANOVA Category P	ANOVA T*C P
<0.01	0.57	0.03

□ Pre ■ Post

Figure 3




Figure 4